SenzaGen H2: Continued growth and aligned with our expectations - Redeye

Redeye provides an update in relation to SenzaGen’s H2 2023 report. We argue the report was solid and aligned with our expectations, where sales came in at SEK26.3m and EBIT at SEK-10.0m. We have made some estimate changes, resulting in an updated fair value range. However, our base case remains at SEK20.

Länk till analysen i sin helhet: https://www.redeye.se/research/979189/senzagen-h2-continued-growth-and-aligned-with-our-expectations?utm_source=finwire&utm_medium=RSS